10x Genomics, Inc. (NASDAQ:TXG) Short Interest Update

10x Genomics, Inc. (NASDAQ:TXG) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 11,320,000 shares, a growth of 34.4% from the January 31st total of 8,420,000 shares. Based on an average daily volume of 2,280,000 shares, the days-to-cover ratio is currently 5.0 days.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 5,092 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now owns 879,482 shares of the company’s stock, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.03% of the company’s stock.

Institutional Trading of 10x Genomics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Signaturefd LLC raised its holdings in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after buying an additional 1,452 shares during the period. GF Fund Management CO. LTD. acquired a new position in 10x Genomics in the 4th quarter valued at about $32,000. Capital Performance Advisors LLP acquired a new position in 10x Genomics in the 3rd quarter valued at about $35,000. Blue Trust Inc. grew its position in 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after acquiring an additional 1,299 shares in the last quarter. Finally, Sound Income Strategies LLC grew its position in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after acquiring an additional 1,330 shares in the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

10x Genomics Trading Up 3.9 %

Shares of TXG opened at $10.93 on Thursday. The firm has a market cap of $1.34 billion, a P/E ratio of -7.19 and a beta of 1.85. 10x Genomics has a 12-month low of $9.27 and a 12-month high of $44.21. The company’s 50-day moving average price is $13.75 and its 200 day moving average price is $16.55.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Equities research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. UBS Group dropped their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Leerink Partnrs cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. Morgan Stanley dropped their price target on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus dropped their price target on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $20.21.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.